38870-31-4

Upstream product

• 134-81-6 benzil 
• 1575-37-7 4-Bromo-benzene-1,2-diamine 
• 38875-53-5 5-bromo-pyridine-2,3-diamine 

Downstream Products

• 139436-81-0 2,3-diphenyl-7-morpholino-5-azaquinoxaline 
• 139436-80-9 2,3-diphenyl-8-morpholino-5-azaquinoxaline 
• 1232-99-1 2,3-diphenylpyrido[3,2-b]pyrazine 
• 52333-34-3 7-bromo-5,6-dihydro-2,3-dimethylpyrido<2,3-b>pyrazine 
• 860293-78-3 [3-(2,3-diphenyl-pyrido[2,3-b]pyrazin-7-yl)-prop-2-ynyl]-dimethyl-amine 
• 59352-87-3 2,3,7-triphenylpyrido[2,3-b]pyrazine 
• 1403993-58-7 C₂₈H₂₃N₃O 
• 1403993-59-8 C₂₉H₁₉N₃ 

Relevant academic research and scientific papers

Light-emitting analogues based on triphenylamine modified quinoxaline and pyridine[2,3-b]pyrazine exhibiting different mechanochromic luminescence

A series of light-emitting analogues, [4-(2,3-diphenyl-quinoxalin-6-yl)-phenyl]-diphenyl-amine (TPA-DPQ) and [4-(2,3-diphenyl-pyrido[2,3-b]pyrazin-7-yl)-phenyl]-diphenyl-amine (TPA-DPP) are synthesized and characterized.TPA-DPQandTPA-DPPpossess similar do

Palladium-catalyzed cross-coupling reactions of 7-bromo-2,3-diphenyl- pyrido[2,3-b]pyrazine

First examples of palladium-catalyzed cross-coupling reactions, such as Suzuki, Sonogashira, Heck and Buchwald-Hartwig reactions, are reported in the pyrido[2,3-b]pyrazine series. This methodology circumvents problems found in uncatalyzed nucleophilic sub

Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines

A series of novel pyrido[2,3-b]pyrazines were synthesized as potential antitumor agents for erlotinib-resistant tumors. Known signal inhibitor compounds from our Nested Chemical Library were tested in phenotypic assays on erlotinib-sensitive PC9 and erlotinib-resistant PC9-ER cell lines to find a compound class to be active on erlotinib resistant cell lines. Based on the screening data, novel pyrido[2,3-b]pyrazines were designed and synthesized. The effect of the substituent position of the heteroaromatic moiety in position 7 and the importance of unsubstituted position 2 of the pyridopyrazine core were explored. Compound 7n had an IC50 value of 0.09 μM for the inhibition of PC9 and 0.15 μM for the inhibition of PC9-ER. We found that some lead compounds of these structures overcome erlotinib-resistance which might become promising drug candidates to fight against NSCLC with EGFR T790M mutation. The signaling network(s) involved in the mechanism(s) of action of these novel compounds in overcoming erlotinib resistance remain to be elucidated.

Pyrido[2,3-b]pyrazine-based full-color fluoresent materials for high-performance OLEDs

High photoluminescence quantum efficiency (PLQY) and simple molecular structure in a full-color emitting material system are two crucial issues for cost-effective multicolor display applications. Herein, a new tailor-made fluorescent core (pyrido[2,3-b]py

Synthesis of quinoxaline, benzimidazole and pyrazole derivatives under the catalytic influence?of biosurfactant-stabilized iron nanoparticles in water

Abstract: We have reported the synthesis, characterization, and catalytic applications of amorphous iron nanoparticles (FeNPs) using aqueous leaves extract of renewable natural resource Boswellia serrata plant. Synthesized FeNPs were stabilized in situ by the addition of aqueous pod extracts of Acacia concinna as a biosurfactant (pH 3.11). The structural investigation of biosynthesized nanoparticles was performed using UV–visible spectroscopy, X-ray diffraction analysis, selected area electron diffraction, energy-dispersive X-ray spectroscopy, scanning electron microscopy, transmission electron microscopy, X-ray photoelectron spectroscopy, thermogravimetric analysis, and BET analysis. The FeNPs were amorphous in nature with average particle size ~ 19?nm and successfully employed as heterogeneous catalyst for the synthesis of quinoxaline, benzimidazole, and pyrazole derivatives in aqueous medium at ambient conditions. The FeNPs could be recycled up to five times with modest change in the catalytic activity. Graphic abstract: [Figure not available: see fulltext.].

HBTU-catalyzed simple and mild protocol for the synthesis of quinoxaline derivatives

HBTU-catalyzed, simple, mild, and effective protocol for the synthesis of quinoxalines has been established. The reaction between 1,2-diamines, benzil, and catalytic amount of HBTU in ethanol resulted into quinoxalines. Various aliphatic, aromatic and het

A zirconium Schiff base complex immobilized on starch-coated maghemite nanoparticles catalyzes heterogeneous condensation of 1,2-diamines with 1,2-dicarbonyl compounds

A magnetically separable zirconium Schiff base nanocatalyst was synthesized under ultrasonic agitation. TEM images revealed a uniform spherical particle shape with average size of 10-14 nm for the as-prepared catalyst. The catalytic performance of ZrOL2@SMNP in the heterogeneous condensation of various 1,2-diamines and 1,2-dicarbonyls for the synthesis of heterocyclic compounds in ethanol has been explored.

Synthesis of quinoxalines and pyrido[2,3-b]pyrazines by SuzukiMiyaura cross-coupling reaction

Abstract: Bromo-substituted quinoxalines and pyrido[2,3-b]pyrazines were synthesized by condensation reactions of aromatic 1,2-diamino and 1,2-diketone compounds. These compounds were used as common intermediates for postcondensation modification by SuzukiMiyaura coupling reaction to form aryl-substituted quinoxalines and pyrido[2,3-b]pyrazines. High-efficiency with improved product yield of aryl-substituted quinoxalines and pyrido[2,3-b]pyrazine derivatives was achieved by conducting a coupling reaction in presence of Pd(dppf)Cl2·CH2Cl2 in tetrahydrofuran (THF) using K2CO3 as base at reflux temperature. Graphical abstract: [Figure not available: see fulltext.].

Bipolar compound containing pyridopyrazine unit and preparation method and application of compound

The invention provides a bipolar compound containing a pyridopyrazine unit. A preparation method of the bipolar compound containing the pyridopyrazine unit comprises the step that the pyridopyrazine unit with an electron-withdrawing effect serves as the b

PYRIDOPYRAZINES AS ANTICANCER AGENTS

The present invention relates to pyridopyrazine derivatives and solvates, hydrates and pharmaceutically acceptable salts thereof, the use of them in the prevention and/or the treatment of cancer diseases, as well as pharmaceutical compositions containing at least one of them as pharmaceutically active agent(s) together with pharmaceutically acceptable carrier, excipient and/or diluents, especially for the prevention and/or treatment of cancer diseases.˙